DDMAC’s New Status as Office of New Drug Promotion to Enhance Enforcement

The FDA division that focuses on eliminating false and misleading statements in promotional materials for prescription drugs has outgrown its designation and will be reorganized and elevated to an office. The Division of Drug Marketing, Advertising and Communications (DDMAC), currently a division under the office of medical policy at CDER, will be replaced by a new office, tentatively named the Office of New Drug Promotion, DDMAC director Thomas Abrams said.
Drug Industry Daily